Form 4: Royalty Pharma CFO Acquires Shares via Equity Awards

Royalty Pharma's EVP & CFO, Terrance P. Coyne, acquired 26,626 Class A Ordinary Shares through the settlement of equity performance awards.

Summary

• Terrance P. Coyne, Executive Vice President and Chief Financial Officer of Royalty Pharma plc (RPRX), acquired 26,626 Class A Ordinary Shares.
• The acquisition occurred on February 11, 2026, and was exempt under Rule 16b-3.
• The shares were acquired at a price of $0, indicating they were part of an equity performance award settlement.
• Following this transaction, Mr. Coyne's reported beneficial ownership in Class A Ordinary Shares includes 1,500 directly held shares and 262,981 indirectly held shares through various entities and family accounts.
• Additionally, Mr. Coyne and family vehicles hold limited partnership interests exchangeable into 6,448,180 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 1,807,277 Class A Ordinary Shares, with the latter subject to vesting conditions.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as it indicates an executive's continued accumulation of company stock, aligning their interests with shareholders, even if it's through a pre-arranged award settlement rather than an open market purchase.

Positives

• The acquisition of shares by a key executive, even through an award settlement, can signal continued alignment of management interests with shareholder value.
• The significant total beneficial ownership, including exchangeable interests, demonstrates a substantial stake held by the CFO in the company's long-term success.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that insider transactions, such as the settlement of equity awards, are common in the pharmaceutical royalty acquisition sector, reflecting standard executive compensation practices. While not an open market purchase, it reinforces executive alignment with company performance.

Related Party Transactions

• The acquisition of shares by Terrance P. Coyne, an Executive Vice President and Chief Financial Officer, is an insider transaction, which is a form of related party dealing.

Stakeholder Impact

• Shareholders: The transaction demonstrates continued executive alignment with shareholder interests through equity ownership.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing reports a routine executive equity award settlement and does not provide new information that would fundamentally alter the investment thesis for Royalty Pharma. While it shows continued insider ownership, it's not an open market purchase signaling new confidence, nor does it reveal any negative developments. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Royalty Pharma, RPRX, Terrance P. Coyne, Insider Transaction, Equity Awards, CFO, Share Acquisition, Beneficial Ownership